Insmed Incorporated

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About INSM

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. 

CEO
William H. Lewis
CEOWilliam H. Lewis
Employees
1,664
Employees1,664
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
1988
Founded1988
Employees
1,664
Employees1,664

INSM Key Statistics

Market cap
20.39B
Market cap20.39B
Price-Earnings ratio
-22.74
Price-Earnings ratio-22.74
Dividend yield
—
Dividend yield—
Average volume
2.88M
Average volume2.88M
High today
—
High today—
Low today
—
Low today—
Open price
$94.02
Open price$94.02
Volume
0.00
Volume0.00
52 Week high
$212.75
52 Week high$212.75
52 Week low
$90.39
52 Week low$90.39

Stock Snapshot

With a market cap of 20.39B, Insmed Incorporated(INSM) trades at $94.00. The stock has a price-to-earnings ratio of -22.74.

During the trading day, Insmed Incorporated(INSM) stock saw an opening price of $94.02, a peak of —, and a bottom of —.

Trading activity shows a volume of 0, compared to an average daily volume of 2.88M.

Over the past 52 weeks, Insmed Incorporated(INSM) stock has traded between a high of $212.75 and a low of $90.39.

Over the past 52 weeks, Insmed Incorporated(INSM) stock has traded between a high of $212.75 and a low of $90.39.

INSM News

Simply Wall St 1d
How Japan Launch Of BRINSUPRI At Insmed Has Changed Its Investment Story - Simply Wall Street

...

How Japan Launch Of BRINSUPRI At Insmed Has Changed Its Investment Story - Simply Wall Street
Simply Wall St 4d
Insmed Stock Looks About Right After Recent Pipeline Progress

has seen its share price swing sharply over recent years, and with fresh clinical and commercial updates landing, the question now is whether the current valuat...

TipRanks 6d
Insmed price target lowered to $213 from $218 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Insmed (INSM) to $213 from $218 and keeps an Overweight rating on the shares. Published first on TheFly – the...

Analyst ratings

96%

of 25 ratings
Buy
96%
Hold
4%
Sell
0%

More INSM News

Benzinga 6d
Top 3 Health Care Stocks That Could Blast Off In October

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a...

Top 3 Health Care Stocks That Could Blast Off In October

People also own

Based on the portfolios of people who own INSM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.